Page last updated: 2024-11-06

cloricromen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cloricromen: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID68876
CHEMBL ID255066
CHEBI ID135628
SCHEMBL ID133346
MeSH IDM0085735

Synonyms (37)

Synonym
proendotel
cloricromene
ad-6
ethyl ((8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)acetate
cloricromene [french]
cloricromen [inn]
ad 6 (pharmaceutical)
8-chlorocarbochromen
cloricromeno [spanish]
cloricromenum [latin]
acetic acid, ((8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-1-benzopyran-7-yl)oxy)-, ethyl ester
cloricromen
68206-94-0
cloricromen (inn)
D07139
NCGC00165769-01
NCGC00165769-02
CHEBI:135628
CHEMBL255066
unii-b9454pe93c
cloricromenum
cloricromeno
b9454pe93c ,
FT-0603198
SCHEMBL133346
cloricromen [mi]
cloricromen [who-dd]
cloricromen [mart.]
DTXSID2048373
GYNNRVJJLAVVTQ-UHFFFAOYSA-N
ethyl [[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxo-2h-1-benzopyran-7-yl]oxy]acetate
ethyl 2-[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxochromen-7-yl]oxyacetate
ethyl 2-(8-chloro-3-(2-(diethylamino)ethyl)-4-methyl-2-oxo-2h-chromen-7-yloxy)acetate
Q5135145
DB13367
o=c(occ)coc1=cc=c(c(o2)=c1cl)c(c)=c(ccn(cc)cc)c2=o
AKOS040745675

Research Excerpts

Overview

Cloricromen is a new drug that inhibits platelet aggregation in man and in experimental thrombosis. Cloricromene is a non-anticoagulant coumarin derivative with anti-platelet and anti-leukocyte properties.

ExcerptReferenceRelevance
"Cloricromen is a new drug that inhibits platelet aggregation in man and in experimental thrombosis. "( No effect of cloricromen on some coagulation parameters in patients with ischaemic cerebrovascular disease.
Carrieri, PB; Coppola, M; D'Alessio, A; Del Vecchio, G; Fazio, N; Grasso, A; Orefice, G; Volpe, G,
)
1.94
"1. Cloricromene is a non-anticoagulant coumarin derivative with anti-platelet and anti-leukocyte properties, which has beneficial effects in various models of ischaemia and shock. "( Dissociation of the anti-ischaemic effects of cloricromene from its anti-platelet activity.
Cirillo, R; Lidbury, PS; Vane, JR, 1993
)
1.17
"Cloricromene is a coumarin derivative without anticoagulant activities that has recently been found to decrease myocardial infarct size after an ischemic-reperfusion injury. "( Cloricromene reduces myocardial infarct size in rabbits when administered during the early reperfusion period.
Castellano, VP; Galaska, HJ; Kim, EJ; Murphy, BA; Royster, RL; Vinten-Johansen, J; Williams, MW; Zvara, DA, 1997
)
3.18
"Cloricromene acid is a catabolite of cloricromene, a coumarin derivative which is active in the cardiovascular system."( Determination of the coumarin derivative cloricromene acid in rabbit plasma and platelets.
Bellato, P; Chen, S; Mariot, R; Moneti, G; Pieraccini, G; Zangirolami, L, 1992
)
1.27
"Cloricromene (AD6) is an investigational drug which inhibits platelet aggregation and release reaction. "( Molecular aspects of cloricromene (AD6) distribution in human platelets and its pharmacological effects.
Banzatto, N; Finesso, M; Mariot, R; Prosdocimi, M; Tessari, F; Travagli, RA; Zatta, A, 1989
)
2.04

Effects

ExcerptReferenceRelevance
"Cloricromene (Clo) has been used to prevent myocardial damage after transient occlusion of the circumflex coronary artery (Cx). "( Beneficial effects of cloricromene in ischemic reperfused myocardium.
Beigelman, R; Cirillo, R; Ferreira, R; Grana, D; Milei, J, 1994
)
2.05

Actions

ExcerptReferenceRelevance
"Cloricromene may inhibit platelet activation induced by several agonists. "( Cloricromene inhibits the activation of human platelets by ADP alone or in combination with adrenaline.
Bazzoni, G; Chen, ZM; Dejana, E; Del Maschio, A; Prosdocimi, M; Zatta, A, 1990
)
3.16

Treatment

Treatment with cloricromene suppressed diabetes-related BRB breakdown by 45%. Treatment significantly lowered retinal TNFalpha, ICAM-1, VEGF, and eNOS.

ExcerptReferenceRelevance
"Cloricromene treatment significantly lowered retinal TNFalpha, ICAM-1, VEGF, and eNOS."( Protective effects of a coumarin derivative in diabetic rats.
Bucolo, C; Cuzzocrea, S; Drago, F; Mazzon, E; Ward, KW, 2009
)
1.07
"Cloricromene treatment reduced the inflammatory cell infiltration and improved histologic status of the ocular tissue."( Effects of cloricromene, a coumarin derivative, on endotoxin-induced uveitis in Lewis rats.
Bucolo, C; Caputi, AP; Cuzzocrea, S; Mazzon, E, 2003
)
1.43
"Cloricromene treatment was associated with a minor body weight loss (p < 0.025) and significantly reduced tissue concentrations of MPO and TNF-alpha (p < 0.02, both)."( A protective effect of the synthetic coumarine derivative Cloricromene against DNB-colitis in the rat.
Campo, GM; Caputi, AP; Cuzzocrea, S; Fries, W; Giofré, MR; Lo Presti, MA; Longo, G; Mazzon, E; Sturiale, S; Sturniolo, GC, 2004
)
1.29
"Treatment with cloricromene suppressed diabetes-related BRB breakdown by 45%."( Protective effects of a coumarin derivative in diabetic rats.
Bucolo, C; Cuzzocrea, S; Drago, F; Mazzon, E; Ward, KW, 2009
)
0.69

Bioavailability

ExcerptReferenceRelevance
" To investigate the ocular bioavailability of cloricromene after inclusion in the polymer matrix, the new nanoparticle system was topically administered in the rabbit eye and compared with an aqueous solution of the same drug."( Eudragit RL100 nanoparticle system for the ophthalmic delivery of cloricromene.
Bucolo, C; Busà, B; Maltese, A; Maugeri, F; Pignatello, R; Puglisi, G, 2004
)
0.82
" Based on the technological results, AD6-loaded Eudragit Retard nanoparticle suspensions appear to offer promise as a means to improving the shelf life and bioavailability of this drug after ophthalmic application."( Preparation and characterization of eudragit retard nanosuspensions for the ocular delivery of cloricromene.
Bucolo, C; Maltese, A; Maugeri, F; Pignatello, R; Puglisi, G; Ricupero, N, 2006
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase kappa isoform 1Homo sapiens (human)Potency9.46620.031622.3146100.0000AID588579
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (67)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (28.36)18.7374
1990's31 (46.27)18.2507
2000's16 (23.88)29.6817
2010's1 (1.49)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.59 (24.57)
Research Supply Index4.32 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (4.23%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other68 (95.77%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 1, First-In-Human, Open-label, Single Ascending Dose and Multidose Study to Assess the Safety, Reactogenicity, and Immunogenicity of the Adenovirus Vector SARS-CoV-2 Investigational Product SC-Ad6-1 Given Via Intramuscular, Intranasal or Inhaled A [NCT04839042]Phase 1190 participants (Anticipated)Interventional2021-06-28Recruiting
A Phase I Study to Assess the Safety and Immunogenicity of New Hepatitis C Virus Vaccine Candidates AdCh3NSmut and Ad6NSmut [NCT01070407]Phase 141 participants (Actual)Interventional2007-07-31Completed
Phase Ib Study to Assess the Safety and Immunogenicity of a Novel HCV Vaccine, Based on the Sequential Injection of Ad6NSmut and MVA-NSmut, Given in Combination With PEG-Interferon Alfa Plus Ribavirin for Re-treatment of Chronic Hepatitis C [NCT01701336]Phase 19 participants (Actual)Interventional2012-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]